- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03041454
Testing New Formats for the Presentation of Research Evidence to Health Care Managers and Policy Makers
A Randomized Trial to Compare the Effects of a Novel Versus Traditional Systematic Review Format on the Ability of Health Care Managers and Policy Makers to Understand and Apply Evidence
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite advances in the conduct and reporting of traditional systematic reviews, current evidence suggests that they are used infrequently by health care managers and policy makers in decision making. Managers and policy makers have suggested that concise presentation positively affects the use of systematic reviews. The purpose of this randomized controlled trial is to assess the impact of a traditional systematic review format compared with the innovative format on the ability of health care managers and policy makers to understand the evidence in the review and apply it to a relevant health care decision making scenario.
The two end-user groups have different formatting needs and we will therefore run 2 parallel studies, randomizing each group separately. Once participants have consented to participate, a computer generated randomization process will allocate them to one of 2 arms (1:1 ratio). Participants will either receive either a traditional format or a novel format. Unequal block randomization will be used and allocation will be concealed through central assignment. Outcomes assessors will be blinded and participants will be blinded to the citation of the review so that the traditional version will not be easily accessible in its original format from the relevant journal.
This study will be the first study to engage health care managers and policy makers in the testing of formats for presentation of research evidence relevant to their needs. The results of the project will help increase the uptake of systematic review results in health care management policy decision-making, ultimately leading to informed decision making and positively impacting the health of Canadians.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Health care managers from the Alberta SCNs, CAHO in Ontario, the RHAs and AQESSS in Quebec and RHAs from BC will be invited to participate.
- Policy makers/analysts from the Ontario, BC, Alberta and Quebec Ministries of Health
Exclusion Criteria:
- Health care managers or policy makers who are unwilling or unable to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Novel systematic review format
A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
|
A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
|
|
No Intervention: Traditional systematic review format
Control participants will be asked to read and answer questions using a traditional systematic review format.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants (health care managers or policy makers) who appropriately consider and apply the evidence from each systematic review format
Time Frame: This measure will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
The proportion of participants (health care managers or policy makers) who appropriately consider and apply the evidence from each systematic review format to the scenario as measured by agreement with an expert panel's recommendation.
A panel of 4 health care managers or policy makers from our research team and 2 content experts.
Their answers will provide the definition of appropriate application of the evidence.
Two investigators who will be blind to allocation will independently determine if the participant's answer agrees with that from the expert panel.
Disagreements will be resolved by a third investigator, independently.
Agreement between investigators will be reported using the kappa statistic.
|
This measure will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comprehension of the review
Time Frame: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Comprehension of the review - defined as the proportion of participants (health care managers or policy makers) who accurately define the bottom line from the systematic review as defined by an expert panel.
A panel of 4 health care managers or policy makers from our research team and 2 content experts.
Their answers will provide the definition of the bottom line from the systematic review.
Two investigators who will be blind to allocation will independently determine if the participant's answer agrees with that from the expert panel.
Disagreements will be resolved by a third investigator, independently.
Agreement between investigators will be reported using the kappa statistic.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Intention to use evidence
Time Frame: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Intention to use evidence - collected through a 12-item likert scale survey.
The survey has good face validity amongst policy makers and managers.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Perceived tentativeness of research findings
Time Frame: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Perceived tentativeness of research findings - collected through a 6-item likert scale survey.
This has been pre-tested to make sure that the items are intelligible to people and to achieve high levels of face validity and reliability.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Provisional opinion about the intervention
Time Frame: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Provisional opinion about the intervention - collected through a 14-item likert scale survey.
This has been pre-tested to make sure that the items are intelligible to people and to achieve high levels of face validity and reliability.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sharon e Straus, Unity Health Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SMH-312381
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.